Intravesical gemcitabine-docetaxel kept 80% of BCG-naive high-risk bladder cancers free of high-grade recurrence at three years

Design

Single-arm, open-label phase 2 trial, 3-year update

Population

25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer

Primary outcome

High-grade recurrence-free survival (secondary end points at 24 and 36 months)

Effect

84% at 24 months (95% CI 63 to 94); 80% at 36 months (58 to 91)

An updated report in The Journal of Urology (22 June 2026) followed a single-arm phase 2 trial of 25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer given weekly intravesical gemcitabine and docetaxel for six weeks, then monthly for two years. Most had high-grade T1 disease and about a third had carcinoma in situ. Median follow-up was 50 months.

High-grade recurrence-free survival was 84% at two years and 80% at three. No patient progressed during treatment; two eventually had cystectomy. Grade 3 adverse events, mainly haematuria and urinary infection, occurred in 20%.

Twenty-five patients and no comparison arm are not enough to replace BCG, and the randomised trial against BCG is the one that matters. But recurring BCG shortages internationally make a durable alternative worth knowing about.

• Keep BCG as standard first-line treatment for high-risk non-muscle-invasive bladder cancer where available.
• Consider gemcitabine-docetaxel when BCG is unavailable, within a unit protocol or trial.
• Warn patients about haematuria and urinary infection during intravesical chemotherapy.
• Maintain cystoscopic surveillance on the same schedule as after BCG.

Why it matters

BCG shortages leave high-risk patients without standard treatment, and this regimen shows durable control.

Don't overread it

A 25-patient single-arm phase 2 trial cannot show equivalence to BCG.

The statistics, in plain English

An 80% three-year recurrence-free rate in 25 patients has a confidence interval from 58% to 91%, wide enough to include results clearly worse than BCG. Without a control arm, there is nothing to compare it with directly.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.